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Childhood tuberculosis contributes signiﬁcantly to the global tuberculosis disease burden but remains challeng-
ing to diagnose due to inadequate methods of pathogen detection in paucibacillary pediatric samples and lack of
a child-speciﬁc host biomarker to identify disease. Accurately diagnosing tuberculosis in children is required to
improve case detection, surveillance, healthcare delivery, and effective advocacy. In May 2014, the National In-
stitutes of Health convened a workshop including researchers in the ﬁeld to delineate priorities to address this
research gap. This blueprint describes the consensus from the workshop, identiﬁes critical research steps to
advance this ﬁeld, and aims to catalyze efforts toward harmonization and collaboration in this area.
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Childhood tuberculosis is estimated to account for 6%
of the tuberculosis caseload globally, and for 4%–21%
of the caseload in the 22 high-incidence countries
that account for 80% of global tuberculosis cases [1].
Mathematical modeling suggests that only 35% of tuber-
culosis cases in children are detected [2]. Improving the
accuracy of tuberculosis diagnosis in children is required
to improve case detection and outcomes, surveillance,
efﬁciency of healthcare delivery, future research, and ef-
fective advocacy.
However, attaining an accurate diagnosis in children
in tuberculosis-endemic settings remains challenging.
There is overlap of the clinical presentation of tubercu-
losis with other common childhood diseases such as
pneumonia, human immunodeﬁciency virus (HIV)–
associated lung disease, and severe malnutrition [3].
Clinical and chest radiographic features are often non-
speciﬁc and subject to variable interpretation [4]. Struc-
tured diagnostic scoring systems based on clinical and
radiologicalﬁndings and tuberculin skin testing showhigh
variability in case yield, with poor agreement between
scoring systems [5]. Microbiological conﬁrmation is pos-
sible in children of all ages, but is rarely attempted due to
perceived difﬁculties in obtaining respiratory specimens
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and because both culture [6] and automated real-time nucleic
acid ampliﬁcation tests are only positive in a proportion of chil-
dren who have been clinically diagnosed with tuberculosis [7–
9]. Current diagnostics that measure immunological responses
following infection with Mycobacterium tuberculosis have un-
certain sensitivity and are unable to distinguish active tubercu-
losis from latent tuberculosis [10]. The clinical distinction
between latent and active tuberculosis is unlikely to be dichot-
omous, especially following recent infection—a common sce-
nario in children.
In 2014, the National Institutes of Health (NIH) of the United
States convened a group of panelists to develop a blueprint for the
process of discovery and implementation of new diagnostic bio-
markers for pediatric tuberculosis. In the 19th century, a “blue-
print” was a reproduction of a technical drawing through a
contact print process on light-sensitive sheets that allowed the
rapid and accurate reproduction of documents but was unable
to reproduce color or shades of gray. This article shares several
similarities with the original blueprint method, inasmuch as it
builds on existing efforts for pediatric diagnostic biomarker dis-
covery, qualiﬁcation, validation, and implementation, but does
not dictate the exact approach in view of the rapidly changing
technological, regulatory, and health implementation realities.
The blueprint presented here outlines the issues facing the ﬁeld
of pediatric tuberculosis biomarker development and is aligned
with the Stop TB Partnership and the World Health Organiza-
tion (WHO) International Roadmap for Tuberculosis Research
[11]. The blueprint covers the following critical steps:
• Deﬁning and prioritizing which biomarkers are needed
• How to select the most appropriate markers for qualiﬁca-
tion and validation
• New and potential future technologies
• Study design considerations
• Collection and storage of suitable specimens
• Biorepository considerations
• Regulatory challenges
The target audience for this article includes researchers,
healthcare providers, funding agencies, and regulatory bodies,
in an effort to coordinate and streamline the challenging pro-
cess of pediatric tuberculosis diagnostic biomarker discovery,
validation, qualiﬁcation, and implementation.
CONSENSUS STATEMENT PREPARATION
Wide consultation was sought in the development of this blue-
print with input from international experts from relevant clinical,
basic science, public health and regulatory ﬁelds, and other stake-
holders. Among the panelists speciﬁcally included were pediatric
tuberculosis clinicians, tuberculosis researchers, HIV research
network representatives, ethicists, representatives from research
funding agencies, and individuals from nongovernmental, advo-
cacy, and community research organizations. Panelists were invit-
ed to a workshop entitled “Pediatric Tuberculosis: Addressing
Research Gaps in Diagnostic TB Biomarkers” organized by the
NIH in Bethesda, Maryland, in May 2014. Prior to the workshop,
conference calls were held to identify key questions for discussion
at the workshop. A table summarizing existing pediatric (and
major adult) specimen repositories was developed (Table 1).
During the workshop, there were timed discussions, including
break-out groups, with statement modiﬁcation in real time.
The statements were reviewed in the subsequent plenary sessions.
Agreement was reached by consensus or by vote.
The consensus questions covered 3 key areas relating to pedi-
atric tuberculosis biomarker research:
1. What are the criteria for the optimal pediatric tuberculosis
biomarkers?
2. What are the challenges and sustainability issues for a pe-
diatric tuberculosis specimen repository?
3. What are the custodianship, ownership, legal, regulatory,
and policy issues relating to such repositories?
This document, which captures the consensus from the
workshop, aims to generate further discussion about pediatric
tuberculosis biomarker research, and to catalyze efforts toward
harmonization and collaboration. An NIH-sponsored Pediatric
TB Biomarker Working Group has been established to assist in
moving this process forward.
THE CHARACTERISTICS OF AN “IDEAL”
BIOMARKER FOR TUBERCULOSIS IN CHILDREN
A biomarker (or set of biomarkers) that could be used to devel-
op an accurate test for tuberculosis in a child would ideally fulﬁll
the following requirements:
• Measurable in a readily obtainable matrix such as blood
(eg, by ﬁngerstick), urine, stool, saliva, buccal mucosal transu-
dates, or exhaled air given the challenges in obtaining respirato-
ry specimens from infants and young children (<5 years).
• Identify M. tuberculosis with high sensitivity and speciﬁc-
ity, independent of age, nutritional status, or HIV status as the
cause of, or contributing factor to, the current illness in children
presenting clinically with pulmonary or extrapulmonary
tuberculosis.
• Distinguish between children with latent tuberculosis (in-
cluding children with latent tuberculosis who have respiratory
symptoms due to another pathogen) and those with active tu-
berculosis disease.
• Suitable for incorporation into a diagnostic platform that
would provide a rapid, accurate result at, or close to, the point
of care.
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Table 1. Repositories From Existing Studies Evaluating Tuberculosis Biomarkers
Reference
Sample
Biorepository UCT Pediatric TB Kenya Pediatric TB
Pneumonia Etiology
Research for Child
Health TB
Grand Challenges in
Global Health GC6-
74 Biomarkers for TB Aeras TB
European Union
Action for
Diseases of
Poverty,
Diagnostics
Consortium–TB
Foundation for
Innovative New
Diagnostics–TBa
Consortium for
Tuberculosis
Biomarkers–TB
Enrollment
type(s)
P P P A, P A, P A, P A A
HIV status,
Positive or
negative
Both Both Both Both Both Both Both Both
Clinical
categories
Suspected TB
cases (n = 1800)
Children <5 y of age
with (1) Suspected
TB (n = 300),
further categorized
as definite,
probable, possible,
unlikely, no TB; (2)
asymptomatic
children (n = 100)
(1) Children with
severe and very
severe pneumonia
and (2) healthy
community
controls
(1) Newly diagnosed
adult pulmonary
TB cases, (2)
HHCs: adults with
TB disease and
healthy controls,
(3) adolescents
(non-HHC)
including
progressors with
TB disease
Vaccine trial
cohorts
(1) Suspected TB
cases and (2)
TB contacts
further
categorized as
TB disease
(culture
positive,
probable or
possible TB),
non-TB
diseases, or
healthy LTBI
Suspected pulmonary
TB further categorized
as (1) TB disease
including (i) Smear
and culture positive;
(ii) smear negative,
culture positive; (2)
clinical diagnosis only,
with response to
treatment (chest
radiograph), (3) not TB
Newly diagnosed
pulmonary TB.
Culture-
confirmed TB
disease
specimens from
clinical trials: TB
Alliance, CDC TB
Trials
Consortium, and
AIDS Clinical
Trials Group
Countries
included
South Africa Kenya South Africa, Zambia,
Kenya, The
Gambia, Mali,
Thailand,
Bangladesh
South Africa, The
Gambia, Malawi,
Uganda, Ethiopia
Sub-Saharan
Africa
South Africa,
Kenya, Malawi
Bangladesh, Brazil,
Moldova Peru, South
Africa, Vietnam,
Zimbabwe. TDR/
WHO TB Specimen
Bank samples:
Bangladesh, Brazil,
Canada, Colombia,
Kenya, Peru, South
Africa, Spain, The
Gambia, Uganda,
Vietnam
To date: South
Africa, Kenya,
Uganda
Subject
follow-up
duration
6 mo if TB
treatment given,
2 mo if TB
treatment not
given
6 mo or until TB
treatment
completion.
Evaluations at 0,
0.5, 2, 6 mo)
Up to 30 d after
hospital discharge
24 mo (HHC
evaluations at 0, 6,
18 mo, index case
evaluations at 0,
12 mo).
Up to 24 mo 6 mo 2–3 mo Samples collection
at treatment
initiation, weeks
2, 4, and 8,
months 4, 6, and
12. Also at time
of relapse or
withdrawal from
study
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Table 1 continued.
Reference
Sample
Biorepository UCT Pediatric TB Kenya Pediatric TB
Pneumonia Etiology
Research for Child
Health TB
Grand Challenges in
Global Health GC6-
74 Biomarkers for TB Aeras TB
European Union
Action for
Diseases of
Poverty,
Diagnostics
Consortium–TB
Foundation for
Innovative New
Diagnostics–TBa
Consortium for
Tuberculosis
Biomarkers–TB
Type of
samples
Whole-blood (EDTA
tube), whole
blood (PAXgene
tube), serum,
induced sputum,
NP swab, urine,
stool, selected
extrapulmonary
specimens
Whole blood
(PAXgene tube),
plasma, serum,
QFT supernatant,
nasopharyngeal
and oropharyngeal
(NP/OP) swabs,
gastric aspirate,
urine, stool
Whole blood,
nasopharyngeal
and oropharyngeal
(NP/OP) swabs,
induced sputum or
gastric aspirate (if
no sputum; cases
only), pleural fluid
(cases only), lung
aspirates (cases
only), urine,
postmortem lung
needle biopsy
Serum, plasma,
PBMC, RNA,
DNA. Most
samples stored at
field sites,
selected samples
at UCT central
repository
PBMC,
whole
blood,
plasma,
serum,
urine
Whole blood
(PAXgene
tubes),
plasma, throat
swabs
Plasma (EDTA), plasma
(P800), serum,
sputum, saliva, urine
Whole blood
(PAXgene tube),
whole blood
(EDTA), whole
blood in QFT
tubes (nil,
mitogen, TB
antigen), sputum,
spot urine
Diagnostic
gold
standard
MGIT culture of 2×
induced sputum
or Xpert of
respiratory
specimen.
MGIT culture and
Xpert MTB/RIF
(suspected TB
cohort, per
participant): NP
aspirate (2),
induced sputum
(2), gastric aspirate
(2), string test (2),
urine (2), stool (2);
MGIT culture on
blood (1)
TB culture TB culture (solid and
liquid),
concentrated
Ziehl-Neelsen
microscopy post-
NALC-NaOH.
TB culture TB culture TB culture (solid or
liquid), concentrated
Ziehl-Neelsen
microscopy post-
NALC-NaOH
TB culture (solid or
liquid)
PI and
contact
PI’s Heather Zar
and Mark Nicol
(Mark.Nicol@uct.
ac.za) (heather.
zar@uct.ac.za)
PI Rinn Song (Rinn.
Song@childrens.
harvard.edu); Ellie
Click (eoc9@cdc.
gov); Kevin Cain
(bvz1@cdc.gov)
PI Katherine O’Brien
(kobrien2@jhu.edu)
Contact: David
Murdoch (David.
murdoch@otago.
ac.nz)
PI Stefan
H. E. Kaufmann
Contacts: Gerhard
Walzl (gwalzl@
sun.ac.za),
Thomas Scriba
(thomas.scriba@
uct.ac.za), Katrina
Downing (Katrina.
Downing@uct.ac.
za)
Contact: Lew
Barker
(LBarker@
aeras.org)
& Heather
Siefers/
Aeras; for
SATVI
Thomas
Scriba
(thomas.
scriba@
uct.ac.za)
Contact: Mike
Levin (m.
levin@
imperial.ac.
uk).
Contact: Eloise Valli
(eloise.valli@
finddiagnostics.org)
Contact: Derek
Ambrosino
(derek.
ambrosino@
tballiance.org)
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PRIORITIES FOR PEDIATRIC TUBERCULOSIS
BIOMARKER DEVELOPMENT/VALIDATION
There is a substantial gap between the requirements for an ideal
pediatric tuberculosis biomarker and currently available bio-
markers. To close this gap, the following priority areas for re-
search were identiﬁed:
1. Biomarkers for the diagnosis of active tuberculosis disease
among symptomatic children (both HIV-infected and uninfect-
ed) should be considered top priority.
2. The optimal biomarker should enable diagnosis of active
tuberculosis disease in all children; however, the highest priority
should be given to young children aged 0–5 years who are
known to have the greatest burden of disease [12], are at highest
risk for developing severe disease, with associated morbidity
and mortality, and are the age group in which diagnostic con-
ﬁrmation of disease is most challenging.
3. Both pulmonary and extrapulmonary tuberculosis should
be targeted for new diagnostics, but the priority should be given
to pulmonary tuberculosis given the disease burden and diag-
nostic challenges highlighted above.
NEWAND POTENTIAL FUTURE TECHNOLOGIES
There has been progress in identifying host and pathogen bio-
markers with diagnostic potential as well as in the development,
optimization, and integration of new and current technologies.
This has resulted in rapid population of the diagnostic pipeline
for tuberculosis [13]. Improvements in current nucleic acid am-
pliﬁcation (NAAT) technologies include the development of
highly sensitive next-generation NAAT platforms [14] and
new portable, battery-operated NAAT platforms with built-in
communication technologies to speed up the communication
of results [15, 16], which could be suitable for low-resource set-
tings. Other promising pathogen detection methods include
molecular detection of small fragments of tuberculosis-speciﬁc
transrenal DNA [17, 18] and ﬂuorogenic enzymatic tests for the
speciﬁc detection of BlaC [19]. The latter is a highly conserved
and speciﬁc class A β-lactamase naturally expressed and secret-
ed by M. tuberculosis. These new technologies are particularly
important because they utilize readily available specimen
types or amplify signal from organisms that are scarce in spec-
imens due to the paucibacillary nature of pediatric tuberculosis.
Other diagnostic approaches not relying on pathogen detec-
tion are also emerging. For example, microRNAs (miRNAs)
have been shown to modulate the pathogenesis of tuberculosis
infection, disease, and treatment response, and such studies
have already been conducted in children. Studies evaluating
the potential for diagnostics based on miRNA proﬁles in
serum, peripheral blood immune cells, and sputum haveTa
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reported that speciﬁc miRNAs show the potential to discrimi-
nate infected from healthy individuals, and active from latent
infection, and to be useful for monitoring response to treatment
[20]. Similarly, pediatric studies have demonstrated that ge-
nomewide host transcriptional RNA signatures in blood can
distinguish tuberculosis from other diseases and from latent tu-
berculosis infection, and that risk scores based on gene expres-
sion may be useful for ruling out tuberculosis [21]. It has also
been recently shown that a T-cell activation marker present
on circulating M. tuberculosis–speciﬁc T cells can discriminate
active from latent infection in children [22]. Given the rapid
emergence of new technologies, there is a need to better deﬁne
the strategy for biomarker selection and validation.
KEY DESIGN FEATURES FOR BIOMARKER
STUDIES
Diagnostic studies in children should be standardized with re-
gard to the key elements of study design such as eligibility cri-
teria, radiological and microbiological assessments, specimen
collection and storage, data collection and analysis, clinical
care, and clinical case deﬁnitions. The Pediatric TB Biomarker
Working Group is currently developing consensus guidelines in
this regard. Case deﬁnitions of disease should preferably follow
the NIH consensus deﬁnitions for diagnostic study categories
for intrathoracic tuberculosis [23], which have recently been re-
vised to deﬁne 3 categories of tuberculosis disease: (1) con-
ﬁrmed tuberculosis (microbiologically conﬁrmed); (2)
unconﬁrmed tuberculosis (formerly possible or probable tuber-
culosis); (3) unlikely tuberculosis [24].
Ideally, prospective cohort studies with adequate follow-up to
monitor response to therapy should be undertaken to enable
accurate, standardized collection of data and specimens. How-
ever, leveraging existing cohorts and biorepositories from well-
characterized cohorts (eg, Table 1) will also be of considerable
value. Children with a wide range of symptoms and clinical
manifestations should be included in studies to cover the full
spectrum of tuberculosis disease. Studies should be done in dif-
ferent epidemiological settings that include a broad range of
frequent nontuberculosis conditions (eg, malnutrition, HIV-
associated infections, bacterial pneumonia, malaria) as differen-
tial diagnoses. Detailed historical, clinical, laboratory, and
radiological characteristics should be collected to enable stan-
dardized case deﬁnitions. A standardized data dictionary and
specimen collection template would be useful to enable meta-
analysis of data from different studies, cohorts, and repositories,
and should be developed by pediatric tuberculosis researchers.
Study design should include follow-up of all children, with
and without tuberculosis infection or disease, not only to
allow collection of sequential specimens, but also to strengthen
the case deﬁnitions for tuberculosis, by evaluating response to
therapy in children treated or not treated for tuberculosis.
The suggested follow-up times for children treated for tubercu-
losis disease include visits at 2 weeks, 2 months, and 6 months
or treatment completion and a visit at 2 months for children not
treated for tuberculosis disease.
COLLECTION AND STORAGE OF SUITABLE
SPECIMENS
A key component of study design is the choice of specimen
type and collection method. Specimens should be collected
bearing in mind that both pathogen and host biomarker detec-
tion strategies may be used, including, for example, proteomic,
metabolomic, and gene expression proﬁling. In children with
pulmonary tuberculosis, M. tuberculosis has been isolated
from a variety of respiratory and alimentary tract specimens,
and potential diagnostic biomarkers can also be detected in
blood products and urine [7, 8, 21, 25–28]. Selection of the
most suitable specimen types for a pediatric tuberculosis diag-
nostic biomarker study should take into account the issues of
feasibility, acceptability, effectiveness, and cost of the collection
procedure under programmatic conditions. In general, this
would include blood (eg, serum, whole blood for RNA), respi-
ratory specimens (eg, induced or spontaneously expectorated
sputum, nasopharyngeal aspirate or swab, gastric aspirate/
lavage, string test), urine, and other extrapulmonary specimens
(when clinically indicated). To facilitate comparison of results
between biomarker studies and thereby increase their useful-
ness, it is important to standardize specimen collection, han-
dling, processing, and storage across studies.
There are many considerations to take into account to assure
standardization. Collection of specimen types should be well doc-
umented, including anatomical location (eg, nasopharyngeal/
oropharyngeal/laryngopharyngeal); specimen content (eg,
“pure” aspirate vs diluted lavage/wash); collection vehicle (eg,
swab tip vs suction catheter); swab type (eg, cotton vs synthetic
tip); additives used (eg, antimicrobial agent, nucleic acid stabil-
izer, buffer); and volume accepted and processed, as volume
can signiﬁcantly impact assay sensitivity. Handling, processing,
and storage of specimens vary by type, and considerations for
standardization include pH (eg, neutralization based on initial
pH); transport time, especially for nonsterile specimens; centrifu-
gation parameters; and refrigeration and storage temperature.
Ideally, standard operating procedures for the collection of
each specimen type should be collaboratively developed, piloted
and reﬁned, and consistently implemented.
Stored specimens may be used not only for tuberculosis bio-
marker discovery and detection, but, as improved diagnostics
for other respiratory pathogens become available, may also be
tested for such pathogens to improve the speciﬁcity of clinical
case deﬁnitions. Research protocols, reviewed by institutional
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review boards, need to incorporate speciﬁc consent for storage
and future testing of samples.
DEVELOPING A SUSTAINABLE
BIOREPOSITORY
The biomarker discovery and validation process would be facil-
itated by the availability of biorepositories containing well-
characterized and appropriate pediatric specimens. Given the
substantial upfront effort and cost involved in carefully char-
acterizing a symptomatic cohort by clinical criteria and in con-
ﬁrming a case of tuberculosis in a child, it is particularly
important to maximize the beneﬁt associated with this initial
investment by establishing repositories for pediatric specimens.
At present, tuberculosis-specimen biorepositories are focused
on samples from adults, or are in the hands of individual inves-
tigators (Table 1), with little coordination and standardization.
A key outcome of the workshop was an initiative to develop a
shared pediatric repository.
Key questions in designing a repository are: What is the scien-
tiﬁc objective of the work and what are the potential biomarker
targets of interest? Scientiﬁc objectives, for example, could in-
clude discovery of new diagnostics for tuberculosis disease or of
markers of treatment response and will guide decisions about
whether to focus more on specimen collection at baseline vs lon-
gitudinal specimen collection [29]. Biomarker targets of interest
will guide decisions about which specimens to collect, how to
store specimens, and whether initial processing is required
prior to biobanking. Practical questions to be addressed in repos-
itory planning are: (1) How many aliquots of each specimen to
biobank and in what volume, based on considerations of known
vs unknown potential applications, cost, and clinical limitations
(eg, blood volume)? (2) Which specimens should be prioritized
in case it is not possible to collect all specimens from every par-
ticipant? and (3) What are the time points for specimen collec-
tion during longitudinal sampling?
The technical differences between methods used to collect,
transport, process, and store specimens in studies may be con-
tributing factors to variation in the published accuracy of diag-
nostic markers [30]. Data collection and process harmonization
are therefore critical for interpretability and comparability of re-
sults. Detailed data on the speciﬁcs of specimen collection are
necessary to determine what potential targets are likely pre-
served in a sample. Similarly, linkage to clinical metadata is
needed to identify the potential suitability of speciﬁc samples
for studies and the interpretation of study ﬁndings.
A large challenge to the integrity of repositories is the re-
quirement for meticulous record-keeping. Potential solutions
to record-keeping challenges include the use of barcode label-
ing, electronic databases to indicate the location of each sample
and to link sample data to clinical metadata, and segregation of
samples by specimen type and aliquot number to facilitate easy
access at a later time.
As a part of ﬁrst steps, it was determined at the workshop that
a Data Sharing Framework needed to be created with agreed-
upon standard procedures and pediatric tuberculosis nomen-
clature, and a Pediatric TB Biomarkers Working Group is
being organized by NIH, including the authors of this manu-
script, other tuberculosis experts, and microbiologists. This
group is currently developing standard nomenclature and oper-
ating procedures for pediatric specimen collection.
The establishment, maintenance, and custodianship of a bio-
repository will require dedicated funding. Funding of a biorepo-
sitory requires careful planning as costs for specimen collection,
handling, and processing for long-term storage, and for data
management and storage, are often not included in the initial
budget of research studies, and speciﬁc funding sources are cur-
rently limited. Appropriate funders or partners will need to be
identiﬁed and key partnerships should be sought with existing
networks, such as the International Maternal, Pediatric, Adoles-
cent AIDS Clinical Trial Network (IMPAACT) and foundations
with experience in running biorepositories, such as the Foundation
for Innovative New Diagnostics (FIND), as well as potential fund-
ers such as the NIH and the Bill & Melinda Gates Foundation.
Considering that prior experience has shown that the creation
and maintenance of such repositories is a large and expensive un-
dertaking, entities such as those listed above could pool resources
and each fund parts of the repository creation and maintenance.
Funders may be more amenable to provide resources when exist-
ing specimens are pooled together in a single repository, as
opposed to generating de novo repositories or funding individual
repositories. A repository team would be needed to plan the es-
tablishment of the repository in detail. This blueprint can be seen
as part of the lobbying exercise to facilitate such funding and may
stimulate the participation of other collaborators. Funding would
have to be for a period of at least 5 years, with clear milestones
and deliverables, culminating in a sample release phase during
which researchers could apply for sample release to facilitate
their test development work. A long-term plan for sustainability
should be developed, which may include contributions from re-
searchers wishing to access samples.
To encourage investigators to submit specimens to biorepo-
sitories, funders could consider making submission of samples
a component of funding opportunities or incentivizing submis-
sion through the provision of supplementary funding.
REGULATORY CHALLENGES FOR PEDIATRIC
BIOREPOSITORIES
Custodianship of a biorepository involves the provision of care-
ful oversight andmanagement of samples from the point of speci-
men collection all the way to the research use of biospecimens and
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the linked data. A plan for selection of an appropriate custodian,
with explicit details on the responsibilities, should be developed
prior to the launch of a biobanking initiative. Policies need to
be in place to safeguard the quality of samples being entered
into the repository and their long-term storage. Additionally, pol-
icies are needed for the appropriate use of biospecimens and data,
while assuring the privacy and conﬁdentiality of participants and
their data. Research data standards, such as those provided by the
Clinical Data Interchange Standards Consortium [31], along with
a data-sharing framework and agreed-upon pediatric tuberculosis
nomenclature, should be established as part of the custodianship
plan. Local and national regulatory bodies may have restrictions
on types of specimens that may be collected as well as the inter-
national exchange of samples. Such regulations vary by country,
by specimen type (eg, host DNA), and by target patient population
(eg, pediatric patients and pregnant women). A well-delineated
custodianship plan can help address some of these issues by pro-
viding to the local and national regulatory bodies the agreed-upon
principles and protocols that govern the biorepository. The Na-
tional Cancer Institute Best Practices for Biospecimen Resources
[32] notes that the “custodian is the trusted intermediary and
caretaker of biospecimens and associated data, and the custodi-
an’s caretaking responsibilities should align with applicable ethi-
cal and policy standards,” adding that the ideal custodian should
be someone other than research investigators or sponsor(s) of the
biospecimen resource (eg, a biospecimen resource manager) to
eliminate potential conﬂicts of interest.
As part of a governance plan for the biorepository, an organi-
zational structure should be delineated that includes a bioreposi-
tory team responsible for planning and managing the repository
as well as a sample access committee that governs access to sam-
ples. These could be modeled on the framework established by
CTB2, a project of the TB Alliance, the CDC’s TB Trials Consor-
tium, and the AIDS Clinical Trials Group of the US National In-
stitute of Allergy and Infectious Diseases (NIAID), NIH. This
project is collecting high-quality patient specimens in late-stage
tuberculosis drug clinical trials where they are linked to detailed,
yet anonymized clinical documentation to enable discovery and
qualiﬁcation of biomarkers for clinical development of improved
tuberculosis treatments for both drug-sensitive and multidrug-
resistant tuberculosis (see http://www.tbbiorepository.org/). The
sample access committee should include scientists knowledgeable
about the research that may arise from the specimens, experi-
enced curators of biorepositories, and experts in epidemiology,
biostatistics, and informatics, among other technical consultants.
Patient advocates and research participants, where feasible,
should be included as members. The governance plan should
describe (1) the methods for safeguarding the integrity of the
samples and associated data, providing protocols used for biospe-
cimen collection and storage; (2) clear procedures for requesting
access to samples and data by investigators; (3) the review process
for sample and data requests, assuring that the composition of a
review committee that evaluates access requests is aligned with the
stated mission/goals of the biobank; (4) policies for the dissemi-
nation of results from research that uses the samples; and (5) re-
sponsible ﬁscal planning for the long-term storage of specimens
and data, as well as plans for securing future funds tomaintain the
repository until samples are depleted. Early planning for the cus-
todianship, governance, and sample access mechanisms will help
mitigate potential legal, ethical, and regulatory complications that
can arise in the future operations of the biorepository.
CONCLUSIONS: CHARTING THEWAYFORWARD
Continued advocacy, collaboration, and communication are
needed to ensure the key elements of the blueprint are adopted
and implemented. Future pediatric tuberculosis biomarker efforts
will require focus on standardization in terms of case deﬁnitions,
specimen collection methods, and clinical data collection, as well
as the adaptability to evaluate new potential biomarkers and
technologies. Early inclusion of donors into the discussion
should emphasize the need of funding not only for diagnostic de-
velopment and pediatric cohorts, but also for building and main-
taining specimen repositories as part of a larger research
network. Developers of new tuberculosis diagnostics should be
involved at early stages to consider ways to integrate new bio-
markers into already existing, adapted, or new platforms.
Given the limited number of pediatric specimens in existing
centralized repositories, there is a clear need to continue to en-
roll children in prospective cohort studies that collect standard-
ized high-quality data and samples and to optimize available
resources. Harmonization of specimen collection methods
and clinical data collection has begun with the formation of a
Pediatric TB Biomarker Working Group and a coordinating
committee from the attendees of this workshop, with the goal
of having uniﬁed standards for evaluating biomarkers from ex-
isting and future repositories. Building on newly discovered
promising biomarkers and on new technologies with a focus
on the clinical challenges in children and the priority areas as
identiﬁed in this blueprint can serve as the initial stages of tu-
berculosis diagnostics development. Successful identiﬁcation of
a child-friendly tuberculosis diagnostic biomarker will require
input, collaboration, and coordination from many stakeholders,
from concept development of the study design to, ultimately,
the development of a point-of-care test appropriate for use in
those regions with the highest burden of pediatric tuberculosis.
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